Friday, November 21, 2008

Breast Cancer

CALGB-40101	Lead group: CALGB
Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 Cycles) Versus Paclitaxel (4 vs. 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial Phase III Randomized Study
IBCSG-24-02	Lead Group: IBCSG
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)
NSABP-B-39	Lead Group: NSABP
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
NSABP-B-42	Lead Group: NSABP
A Clinical trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
PACCT-1	Lead Group: ECOG
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
S0226	Lead Group: SWOG
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer
A Phase 3 study of SU011248 in combination with paclitaxel versus bevacizumab with paclitaxel in the first-line advanced disease setting in patients having breast cancer.

We participate in many NCI sponsored trials. Please feel free to contact Leann Ross at (304) 399-6617 or leann.ross@chhi.org or Barbara Payne at (304) 399-6637.

For more information about the clinical trials listed please go to http://www.clinicaltrials.gov.